Immatics Biotechnologies Gmbh

Immatics US, Inc.

Sabrina Kuttruff-Coqui

Norbert Hilf

Toni Weinschenk

Jens Fritsche

Oliver Schoor

Harpreet Singh

Colette Song

Steffen Walter

Melinda Mata

Yannick Bulliard

Monique Dao

Sarah Missell

Aleksandra Nowicka

Aleksandra Norwicka

Sarah Missel

The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

Methods for expanding and activating γσ T cells for the treatment of cancer and related malignancies

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Personalized immunotherapy against several neuronal and brain tumors

The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of &#x3b3;&#x3b4; T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of &#x3b3;&#x3b4; T cells while depleting &#x3b1;- and/or &#x3b2;-TCR positive cells. T cell populations comprising expanded &#x3b3;&#x3b4; T cell and depleted or reduced &#x3b1;- and/or &#x3b2;-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

Methods for expanding and activating &#x3b3;&#x3b4; T cells for the treatment of cancer and related malignancies

Growing community of inventors

Filderstadt-Sielmingen, Germany

Sabrina Kuttruff-Coqui